Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 291

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms

Sausville, Edward A., Arbuck, Susan G., Messmann, Richard, Headlee, Donna, Bauer, Kenneth S., Lush, Richard M., Murgo, Anthony, Figg, William D., Lahusen, Tyler, Jaken, Susan, Jing, Xiu-xian, Roberge, Michel, Fuse, Eiichi, Kuwabara, Takashi, Senderowicz, Adrian M.·2001·Journal of Clinical Oncology

Abstract

PURPOSE: To define the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of the novel protein kinase inhibitor, UCN-01 (7-hydroxystaurosporine), administered as a 72-hour continuous intravenous infusion (CIV). PATIENTS AND METHODS: Forty-seven patients with refractory neoplasms received UCN-01 during this phase I trial. Total, free plasma, and salivary concentrations were determined; the latter were used to address the influence of plasma protein binding on peripheral tissue distribution. The phosphorylation state of the protein kinase C (PKC) substrate alpha-adducin and the abrogation of DNA damage checkpoint also were assessed. RESULTS: The recommended phase II dose of UCN-01 as a 72-hour CIV is 42.5 mg/m 2/d for 3 days. Avid plasma protein binding of UCN-01, as measured during the trial, dictated a change in dose escalation and administration schedules. Therefore, nine patients received drug on the initial 2-week schedule, and 38 received drug on the recommended 4-week schedule. DLTs at 53 mg/m 2/d for 3 days included hyperglycemia with resultant metabolic acidosis, pulmonary dysfunction, nausea, vomiting, and hypotension. Pharmacokinetic determinations at the recommended dose of 42.5 mg/m 2/d for 3 days included mean total plasma concentration of 36.4 μM (terminal elimination half-life range, 447 to 1176 hours), steady-state volume of distribution of 9.3 to 14.2 L, and clearances of 0.005 to 0.033 L/h. The mean total salivary concentration was 111 nmol/L of UCN-01. One partial response was observed in a patient with melanoma, and one protracted period ( > 2.5 years) of disease stability was observed in a patient with alk-positive anaplastic large-cell lymphoma. Preliminary evidence suggests UCN-01 modulation of both PKC substrate phosphorylation and the DNA damage-related G 2 checkpoint. CONCLUSION: UCN-01 can be administered safely as an initial 72-hour CIV with subsequent monthly doses administered as 36-hour infusions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2001.19.8.2319

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 291

Metadata

Authors
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X.-X., Roberge, M., Fuse, E., Kuwabara, T., & Senderowicz, A. M.
Venue
Journal of Clinical Oncology
Published
2001-04-15
Volume
19
Issue
8
Pages
2319-2333
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1896635905
Cited by
291
References
33
FWCI
9.66
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms. https://app.cochat.ai/papers/10.1200/jco.2001.19.8.2319
The paper
Sausville, E. A., Arbuck, S. G., Messmann, R., Headlee, D., Bauer, K. S., Lush, R. M., Murgo, A., Figg, W. D., Lahusen, T., Jaken, S., Jing, X.-X., Roberge, M., Fuse, E., Kuwabara, T., & Senderowicz, A. M. (2001). Phase I Trial of 72-Hour Continuous Infusion UCN-01 in Patients With Refractory Neoplasms. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2001.19.8.2319

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.